Erythropoietin ameliorates renal interstitial fibrosis via the inhibition of fibrocyte accumulation

Molecular Medicine Reports

Volumn 11, Issue 5, 2015, Pages 3860-3865

  Geng, Xu Chang ^a   Hu, Zhou Pang ^b   Lian, Guo Yong ^a  

^a Central Hospital of Wuhan   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Chemokine; Erythropoietin; Fibrocyte; Renal fibrosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; CXCL16 CHEMOKINE; FIBRONECTIN; MESSENGER RNA; PROTEIN; RECOMBINANT ERYTHROPOIETIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; ALPHA CHEMOKINE; CXCL16 PROTEIN, HUMAN; ERYTHROPOIETIN; RECOMBINANT PROTEIN; SCAVENGER RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATTENUATION; BODY WEIGHT; BONE MARROW CELL; CELLS; CONTROLLED STUDY; DRUG EFFICACY; EXTRACELLULAR MATRIX; KIDNEY FIBROSIS; KIDNEY INTERSTITIUM; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STAINING; SURGICAL TECHNIQUE; UNILATERAL URETERAL OBSTRUCTION; URETER OBSTRUCTION; ANIMAL; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENETICS; HUMAN; KIDNEY DISEASES; METABOLISM; PATHOLOGY;

ANIMALIA; MUS;

ANIMALS; CHEMOKINES, CXC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ERYTHROPOIETIN; FIBROSIS; HUMANS; KIDNEY DISEASES; MALE; MICE; MYOFIBROBLASTS; RECEPTORS, SCAVENGER; RECOMBINANT PROTEINS;

EID: 84922324308     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3157     Document Type: Article

References (33)

1. Duffield JS: Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest 124: 2299-2306, 2014.
2. Boor P and Floege J: The renal (myo-) fibroblast: a heterogeneous group of cells. Nephrol Dial Transplant 27: 3027-3036, 2012.
3. Grgic I, Duffield JS and Humphreys BD: The origin of interstitial myofibroblasts in chronic kidney disease. Pediatr Nephrol 27: 183-193, 2012.
4. Bellini A and Mattoli S: The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 87: 858-870, 2007.
5. Pilling D and Gomer RH: Differentiation of circulating monocytes into fibroblast-like cells. Methods Mol Biol 904: 191-206, 2012.
6. Iwano M, Plieth D, Danoff TM, Xue C, Okada H and Neilson EG: Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 110: 341-350, 2002.
7. Li J, Deane JA, Campanale NV, Bertram JF and Ricardo SD: The contribution of bone marrow-derived cells to the development of renal interstitial fibrosis. Stem Cells 25: 697-706, 2007.
8. Sakai N, Wada T, Yokoyama H, et al: Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc Natl Acad Sci USA 103: 14098-14103, 2006.
9. Chen G, Lin SC, Chen J, et al: CXCL16 recruits bone marrow-derived fibroblast precursors in renal fibrosis. J Am Soc Nephrol 22: 1876-1886, 2011.
10. Reich B, Schmidbauer K, Rodriguez Gomez M, et al: Fibrocytes develop outside the kidney but contribute to renal fibrosis in a mouse model. Kidney Int 84: 78-89, 2013.
11. Yang J, Lin SC, Chen G, et al: Adiponectin promotes monocyte-to-fibroblast transition in renal fibrosis. J Am Soc Nephrol 24: 1644-1659, 2013.
12. Oba S, Suzuki E, Nishimatsu H, et al: Renoprotective effect of erythropoietin in ischemia/reperfusion injury: possible roles of the Akt/endothelial nitric oxide synthase-dependent pathway. Int J Urol 19: 248-255, 2012.
13. Kaynar K, Aliyazioglu R, Ersoz S, et al: Role of erythropoietin in prevention of amikacin-induced nephropathy. J Nephrol 25: 744-749, 2012.
14. Wang W and Zhang J: Protective effect of erythropoietin against aristolochic acid-induced apoptosis in renal tubular epithelial cells. Eur J Pharmacol 588: 135-140, 2008.
15. Imamura R, Isaka Y, Sandoval RM, et al: A nonerythropoietic derivative of erythropoietin inhibits tubulointerstitial fibrosis in remnant kidney. Clin Exp Nephrol 16: 852-862, 2012.
16. Chen CL, Chou KJ, Lee PT, et al: Erythropoietin suppresses epithelial to mesenchymal transition and intercepts Smad signal transduction through a MEK-dependent mechanism in pig kidney (LLC-PK1) cell lines. Exp Cell Res 316: 1109-1118, 2010.
17. Kitamura H, Isaka Y, Takabatake Y, et al: Nonerythropoietic derivative of erythropoietin protects against tubulointerstitial injury in a unilateral ureteral obstruction model. Nephrol Dial Transplant 23: 1521-1528, 2008.
18. Park SH, Choi MJ, Song IK, et al: Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting TGF-beta-induced epithelial-to-mesenchymal transition. J Am Soc Nephrol 18: 1497-1507, 2007.
19. Chevalier RL, Forbes MS and Thornhill BA: Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 75: 1145-1152, 2009.
20. Grande MT, Fuentes-Calvo I, Arévalo M, et al: Deletion of H-Ras decreases renal fibrosis and myofibroblast activation following ureteral obstruction in mice. Kidney Int 77: 509-518, 2010.
21. Kim DH, Moon SO, Jung YJ, et al: Mast cells decrease renal fibrosis in unilateral ureteral obstruction. Kidney Int 75: 1031-1038, 2009.
22. Li L, Huang L, Sung SS, et al: The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int 74: 1526-1537, 2008.
23. Formentini I, Bobadilla M, Haefliger C, et al: Current drug development challenges in chronic kidney disease (CKD) - identification of individualized determinants of renal progression and premature cardiovascular disease (CVD). Nephrol Dial Transplant 27 Suppl 3: iii81-iii88, 2012.
24. Strutz F and Zeisberg M: Renal fibroblasts and myofibroblasts in chronic kidney disease. J Am Soc Nephrol 17: 2992-2998, 2006.
25. Meran S and Steadman R: Fibroblasts and myofibroblasts in renal fibrosis. Int J Exp Pathol 92: 158-167, 2011.
26. Kriz W, Kaissling B and Le Hir M: Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J Clin Invest 121: 468-474, 2011.
27. Broekema M, Harmsen MC, van Luyn MJ, et al: Bone marrow-derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen I after ischemia/reperfusion in rats. J Am Soc Nephrol 18: 165-175, 2007.
28. Niedermeier M, Reich B, Rodriguez Gomez M, et al: CD4+ T cells control the differentiation of Gr1+ monocytes into fibrocytes. Proc Natl Acad Sci USA 106: 17892-17897, 2009.
29. Bucala R, Spiegel LA, Chesney J, Hogan M and Cerami A: Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1: 71-81, 1994.
30. Wada T, Sakai N, Matsushima K and Kaneko S: Fibrocytes: a new insight into kidney fibrosis. Kidney Int 72: 269-273, 2007.
31. Chung AC and Lan HY: Chemokines in renal injury. J Am Soc Nephrol 22: 802-809, 2011.
32. Phillips RJ, Burdick MD, Hong K, et al: Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 114: 438-446, 2004.
33. Boor P, Ostendorf T and Floege J: Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 6: 643-656, 2010.